FreeStyle Libre 3
Anna Nguyen, John R. White
Abstract
Clinical Pharmacology Update| October 27 2022 FreeStyle Libre 3 Anna Nguyen; Anna Nguyen Search for other works by this author on: This Site PubMed Google Scholar John R. White John R. White Corresponding author: John R. White, [email protected] Search for other works by this author on: This Site PubMed Google Scholar Corresponding author: John R. White, Clin Diabetes 2023;41(1):127–128 https://doi.org/10.2337/cd22-0102 PubMed: 36714257 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Cite Icon Cite Get Permissions Citation Anna Nguyen, John R. White; FreeStyle Libre 3. Clin Diabetes 2 January 2023; 41 (1): 127–128. https://doi.org/10.2337/cd22-0102 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsClinical Diabetes Search Advanced Search The U.S. Food and Drug Administration (FDA) cleared the FreeStyle Libre 3 real-time continuous glucose monitoring (CGM) system (Abbott Diabetes Care) for use in May 2022. This system is an update of the FreeStyle Libre 2 and offers CGM with alarm capability for current or impending high and low glucose levels. The Libre 3 system measures glucose levels every minute and automatically sends the results to a smartphone without requiring users to scan the sensor to see their glucose concentrations. In contrast, the Libre 2 is an intermittently scanned, or "flash" CGM system that requires users to scan the sensor with a smartphone or reader device (1,2). The FreeStyle Libre 3 is a single-use, disposable sensor that is applied to the back of the upper arm and can be worn for 14 days. This device is much more convenient than the previous iteration of the system... You do not currently have access to this content.